News | April 29, 2023
Evonik starts construction of new U.S. facility for pharmaceutical lipids
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
This agreement is in addition to the $92 million filling line expansion announced in November 2021
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated
